GlassScriptPhysician profile
Tony L Walden
NPI 1104898170
$2,412.76
in general payments reported to CMS, 2019-2025
8 companies · $135 in 2025
The $135 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,061 · 2021: $24.26 · 2022: $101 · 2023: $92.31 · 2025: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $227.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Minimed, INC. | $1,997.57 | 2019 | |
| Lilly USA, LLC | $138.51 | 2022-2023 | Mounjaro |
| Idorsia Pharmaceuticals US INC | $134.92 | 2025 | Tryvio |
| Shire North American Group INC | $63.10 | 2019 | |
| Horizon Therapeutics Plc | $24.26 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.09 | 2023 | |
| Cequr Corporation | $18.26 | 2023 | Cequr Simplicity |
| Antares Pharma, INC. | $14.05 | 2023 | Tlando, Xyosted, Nocdurna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tony Walden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.